Medicinal chemistry strategies towards the development of non-covalent SARS-CoV-2 Mpro inhibitors
Description
The main protease (M^(pro)) of SARS-CoV-2 is an attractive target in anti-COVID-19 therapy for its high conservation and major role in the virus life cycle. The covalent M^(pro) inhibitor nirmatrelvir (in combination with ritonavir, a pharmacokinetic
